The binding results of pazopanib are discussed in section "Additional focus on known HLA-B*57 01 HLA-B*57 01ucloxactives and Pazopanib".
We have recently reported a similar set of binding results for the N-deacetylated FAF.
In the case of GHR, ligand binding results in the activation of Jak2 molecules [12] that in turn phosphorylate each other's tyrosine residues, the receptor's cytosolic tail and downstream signalling molecules [13].
The simulations also revealed that substrate binding results in the formation of one of the Na+ binding sites (Na2 site) at a position between two short helices.
In this case, ligand binding results in internalization of the ligand-receptor complex, proteolysis of the ligand, and eventual recycling of the receptor to the surface [13], [36].
Activation of the receptors by ephrin binding results in the phosphorylation of the receptor tyrosine residues.
Binding results in the degradation of the target mRNA and inhibition of translation [2].
This binding results in the recruitment of a SKP1-CULLIN-FBOX (SCF) ubiquitin ligase, which ubiquitinates the AUX/IAA protein, targeting it for degradation.
N and Delta binding results in the release of the N intracellular domain (Nintra) from the cell surface.
Binding results in the activation of PCS, which polymerizes GSH molecules into phytochelatins (PCs).
